ANDREAS SIDIROPOULOS: Open Payments
NPI 1871525832 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$722,449 in 580 payments from 7 companies in 2025. Trend: 2023 $431,959 · 2024 $558,499 · 2025 $722,449
Speaker / faculty: $516,944Travel & lodging: $146,044Consulting: $28,453Honoraria: $18,988Food & beverage: $12,020
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 229 | $282,661 |
| ABBVIE INC. | 130 | $135,980 |
| E.R. Squibb & Sons, L.L.C. | 76 | $114,381 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 82 | $114,238 |
| Alkermes, Inc. | 44 | $54,143 |
| Axsome Therapeutics, Inc. | 18 | $21,022 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
Products named: FANAPT, VRAYLAR, CAPLYTA, COBENFY, LYBALVI, Auvelity, ARISTADA, REXULTI.
Industry payments across MI — which companies pay providers there.
